Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts

Transplantation

Volumn 95, Issue 2, 2013, Pages 341-346

  Lawrence, Christopher ^a   Willicombe, Michelle ^a   Brookes, Paul A ^a   Santos Nunez, Eva ^a   Bajaj, Retesh ^a   Cook, Terry ^a   Roufosse, Candice ^a   Taube, David ^a   Warrens, Anthony N ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Antibody; Complement; Rejection; Transplant

Indexed keywords

ALEMTUZUMAB; COMPLEMENT COMPONENT C4D; HLA ANTIBODY; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS;

ADULT; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION FREE SURVIVAL; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE;

ADULT; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BIOLOGICAL MARKERS; BIOPSY; COMPLEMENT ACTIVATION; COMPLEMENT C4B; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872913735     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182743cfa     Document Type: Article

References (22)

1. Rashid A, Sengar DP, Couture RA, et al. Pretransplantation sensitization by HLA and non-HLA antigens and its correlation with graft survival. Transplant Proc 1978; 10: 501.
2. Sanfilippo F, Goeken N, Niblack G, et al. The effect of first cadaver renal transplant HLA-A, B match on sensitization levels and retransplant rates following graft failure. Transplantation 1987; 43: 240.
3. O'Boyle PJ, Smith JD, Danskine AJ, et al. De novo HLA sensitization and antibody mediated rejection following pregnancy in a heart transplant recipient. Am J Transplant 2010; 10: 180.
4. Ishizaka K, Tomioka H, Ishizaka T. Mechanisms of passive sensitization. I. Presence of IgE and IgG molecules on human leukocytes. J Immunol 1970; 105: 1459.
5. Honman K, Parker KC, Becker KG, et al. Identification of an epitope derived from human proteolipid protein that can induce autoreactive CD8+ cytotoxic T lymphocytes restricted by HLA-A3: evidence for cross-reactivity with an environmental microorganism. J Neuroimmunol 1997; 73: 7.
6. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
7. Kushihata F, Watanabe J, Mulder A, et al. Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential. Transplantation 2004; 78: 995.
8. Bray RA, Lebeck LK, Gebel HM. The flow cytometric crossmatch. Dual-color analysis of T cell and B cell reactivities. Transplantation 1989; 48: 834.
9. Willicombe M, Brookes P, Santos-Nunez E, et al. Am J Transplant 2011; 11: 470.
10. Porter RR, Reid KB. Activation of the complement system by antibody- antigen complexes: the classical pathway. Adv Protein Chem 1979; 33: 1.
11. Solez K, Colvin RB, Racussen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
12. Bohmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091.
13. Wahrmann M, Exner M, Regele H, et al. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J Immunol Methods 2003; 275: 149.
14. Rose ML, Smith JD. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009; 70: 605.
15. Bartel G, Wahrmann M, Exner M, et al. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation 2007; 83: 727.
16. Smith JD, Hamour IM, Banner NR, et al. C4d fixing, luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809.
17. Honger G, Wahrmann M, Amico P, et al. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010; 89: 1471.
18. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438.
19. Howell WM, Harmer A, Briggs D, et al. British Society for Histocompatibility & Immunogenetics and British Transplantation Society Guidelines for the Detection and Characterisation of Clinically Relevant Antibodies in Allotransplantation. Int J Immunogenet 2010; 37: 435.
20. Bradley JA, Baldwin WM, Bingaman A, et al. Antibody-mediated rejection-an ounce of prevention is worth a pound of cure. Am J Transplant 2011; 11: 1131.
21. Bartel G, Wahrmann M, Exner M, et al. In vitro detection of C4dfixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts Am J Transplant 2008; 8: 41.
22. Yabu JM, Higgins, JP, Chen G, et al. Ciq-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after transplantation. Transplantation 2011; 91: 342Y347.